ArticleMethods in molecular biology (Clifton, N.J.)2025
Proteomics by qPCR Using the Proximity Extension Assay (PEA).
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Bioassays in Allergy: Technical Characteristics, Limitations, and Pathways to Clinical Implementation-An EAACI Position Paper.Clinical and translational allergy · 2026Review
- Multi-omics integration of proteomics and metabolomics in pediatric health and disease.Communications medicine · 2026Review
- Review
- Multi-omics-driven precision medicine.iMeta · 2026Review
- Analytical Methods for Fluid Biomarkers in Alzheimer's Disease from Discovery to Clinical Implementation.International journal of molecular sciences · 2026Review
- Review
- A Sequential Proteomic Relay Defines a Decade-long Pre-diagnostic Window for Pancreatic Cancer.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Proximity Extension Assay (PEA) is an innovative technology developed by Olink Proteomics that has revolutionized proteomics research. This method enables the simultaneous detection of hundreds of proteins using a minimal sample volume (1 microliter), combining the specificity of antibody-based immunoassays with the sensitivity of quantitative PCR (qPCR). The PEA process relies on the binding of two antibodies, each conjugated with unique DNA sequences, to a target protein. Upon proximity, these DNA sequences hybridize, forming a molecular barcode that is subsequently amplified by PCR, ensuring high specificity and minimizing cross-reactivity-an issue commonly encountered in multiplexed immunoassays. This chapter provides a detailed overview of the technical and methodological aspects of PEA, including the incubation, extension, amplification, and detection steps, as well as the quality control measures implemented in the Olink
Indexed as
Identifiers
40601148What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.